(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) rose 9.5% to $4.61 at 11:56 EST on Friday, after five consecutive sessions in a row of losses. NASDAQ is sliding 0.24% to $11,257.74, after two sequential sessions in a row of gains. This seems, at the moment, a somewhat negative trend trading session today.

TherapeuticsMD’s last close was $4.21, 89.06% below its 52-week high of $38.50.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Earnings per Share

TherapeuticsMD’s trailing 12 months profit per share is $-0.666

Revenue growth

The year-on-year revenue growth for quarterly declined 2.7%. We now have 86.42M in the 12 trailing months.


Today’s last reported volume for TherapeuticsMD is 27286 which is 61.99% below its average volume of 71804.

More news about TherapeuticsMD (TXMD).